NYSE:MRK

Merck & Co., Inc. - MRK Stock Forecast, Price & News

$88.93

-0.26 (-0.29%)

(As of 08/11/2022 12:00 AM ET)

Add

Compare

Today's Range: $87.36
▼
$89.82
50-Day Range: $84.50
▼
$94.96
52-Week Range: $70.89
▼
$95.72

Volume: 7.31 million shs
Average Volume: 8.86 million shs
Market Capitalization: $225.28 billion

P/E Ratio: 13.62
Dividend Yield: 3.09%
Price Target: $97.44

Merck & Co., Inc. MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.61 Rating Score
Upside/Downside: 9.6% Upside
$97.44 Price Target
Short Interest: Healthy
0.66% of Shares Sold Short
Dividend Strength: Strong
Based on Four Factors
Sustainability: -2.29
Upright™ Environmental Score
News Sentiment: 0.46
Based on 8 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: -1.64%
From $7.31 to $7.19 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.69 out of 5 stars

Medical Sector

93rd out of 1,112 stocks

Pharmaceutical Preparations Industry

33rd out of 544 stocks

2.3

Analyst's Opinion

Consensus Rating
Merck & Co., Inc. has received a consensus rating of Buy. The company's average rating score is 2.61, and is based on 9 buy ratings, 8 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $97.44, Merck & Co., Inc. has a forecasted upside of 9.6% from its current price of $88.93.
Amount of Analyst Coverage
Merck & Co., Inc. has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

5.0

Short Interest

Percentage of Shares Shorted
0.66% of the outstanding shares of Merck & Co., Inc. have been sold short.
Short Interest Ratio / Days to Cover
Merck & Co., Inc. has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Merck & Co., Inc. has recently decreased by 17.41%, indicating that investor sentiment is improving significantly.

4.2

Dividend Strength

Dividend Yield
Merck & Co., Inc. pays a meaningful dividend of 3.09%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Merck & Co., Inc. has been increasing its dividend for 12 years.
Dividend Coverage
The dividend payout ratio of Merck & Co., Inc. is 42.27%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Merck & Co., Inc. will have a dividend payout ratio of 38.39% next year. This indicates that Merck & Co., Inc. will be able to sustain or increase its dividend.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Merck & Co., Inc. has received a 60.98% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Pembrolizumab", "Clinical research services for infectious diseases", "HPV vaccines", and "DPP-4 inhibitors" products. See details.
Environmental Sustainability
The Environmental Impact score for Merck & Co., Inc. is -2.29.

2.5

News and Social Media Coverage

News Sentiment
Merck & Co., Inc. has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 8 news articles for Merck & Co., Inc. this week, compared to 15 articles on an average week.
Search Interest
149 people have searched for MRK on MarketBeat in the last 30 days. This is an increase of 34% compared to the previous 30 days.
MarketBeat Follows
131 people have added Merck & Co., Inc. to their MarketBeat watchlist in the last 30 days. This is an increase of 212% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Merck & Co., Inc. insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.29% of the stock of Merck & Co., Inc. is held by insiders.
Percentage Held by Institutions
72.88% of the stock of Merck & Co., Inc. is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Merck & Co., Inc. are expected to decrease by -1.64% in the coming year, from $7.31 to $7.19 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Merck & Co., Inc. is 13.62, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 137.11.
Price to Earnings Ratio vs. Sector
The P/E ratio of Merck & Co., Inc. is 13.62, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 109.57.
Price to Earnings Growth Ratio
Merck & Co., Inc. has a PEG Ratio of 1.21. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Merck & Co., Inc. has a P/B Ratio of 5.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Merck & Co., Inc. (NYSE:MRK) Stock

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on MRK. Daiwa Capital Markets upgraded shares of Merck & Co., Inc. from a "neutral" rating to a "buy" rating and raised their target price for the company from $89.00 to $102.00 in a research note on Wednesday, July 6th. Morgan Stanley lifted their price objective on shares of Merck & Co., Inc. from $88.00 to $92.00 and gave the stock an "equal weight" rating in a research note on Friday, July 29th. UBS Group lifted their price objective on shares of Merck & Co., Inc. from $76.00 to $98.00 and gave the stock a "neutral" rating in a research note on Monday, July 18th. Atlantic Securities lifted their price objective on shares of Merck & Co., Inc. from $105.00 to $110.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 13th. Finally, SVB Leerink reiterated an "outperform" rating and set a $102.00 price objective on shares of Merck & Co., Inc. in a research note on Monday, June 6th. Eight analysts have rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Merck & Co., Inc. has an average rating of "Moderate Buy" and a consensus price target of $97.44.

Merck & Co., Inc. Trading Down 0.3 %

NYSE:MRK opened at $88.93 on Friday. Merck & Co., Inc. has a 1 year low of $70.89 and a 1 year high of $95.72. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.39 and a quick ratio of 1.14. The company has a fifty day moving average of $90.09 and a 200 day moving average of $85.56. The company has a market capitalization of $225.28 billion, a PE ratio of 13.62, a P/E/G ratio of 1.21 and a beta of 0.32.

Merck & Co., Inc. (NYSE:MRK - Get Rating) last released its quarterly earnings data on Thursday, July 28th. The company reported $1.87 earnings per share for the quarter, beating analysts' consensus estimates of $1.69 by $0.18. Merck & Co., Inc. had a net margin of 29.00% and a return on equity of 48.45%. The company had revenue of $14.59 billion during the quarter, compared to analysts' expectations of $13.85 billion. During the same quarter in the previous year, the company earned $1.31 earnings per share. The firm's revenue for the quarter was up 28.0% on a year-over-year basis. Research analysts forecast that Merck & Co., Inc. will post 7.31 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 7th. Shareholders of record on Thursday, September 15th will be issued a $0.69 dividend. The ex-dividend date is Wednesday, September 14th. This represents a $2.76 dividend on an annualized basis and a yield of 3.10%. Merck & Co., Inc.'s payout ratio is 42.27%.

Receive MRK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merck & Co., Inc. and its competitors with MarketBeat's FREE daily newsletter.

MRK Stock News Headlines

August 3, 2022 | marketbeat.com

3 Pharma Stocks' Post-Earnings Price Moves (MRK)

The health care sector is participating in the S&P's nascent rally, but pharmaceuticals AbbVie, Merck and Pfizer are holding up well relative to the market.

July 28, 2022 | marketbeat.com

Merck beats expectations, helped by Keytruda sales

Merck is posting second-quarter sales that easily topped Wall Street expectations, boosted by sales growth of some of its key drugs

August 12, 2022 | Investing Trends (Ad)

Investors See Opportunity in Huge Global Demand for Lithium

The global lithium market is projected to surge 500% due to a growing need for lithium-filled batteries. And one junior mining company in a renowned location in South America is in the right place at the right time to capitalize on this megatrend.

July 23, 2022 | marketbeat.com

Three Watchlist Stocks to Capitalize on Sector Rotation

Sector rotation is a common market event based on the theory that economies move in cycles. Here are three stocks, one apiece, from sectors that institutions are rotating into.

July 12, 2022 | dividendstocks.com

Is Merck & Co. Inc. (NYSE: MRK) a Great Long-Term Dividend Pick?

August 11, 2022 | finance.yahoo.com

Haemonetics (HAE) Q1 Earnings Beat Estimates, Margins Up

August 10, 2022 | finance.yahoo.com

Is it a Good Choice to Invest in Merck & Co. (MRK)?

August 10, 2022 | finance.yahoo.com

10 defensive stocks that can also provide you with growth and dividends over the long term

August 12, 2022 | Investing Trends (Ad)

Russia Ignites West's Battle for Energy Independence

Putin's invasion of Ukraine has revealed the West's dependence on Russia for their energy needs. Western countries are now scrambling for stable, renewable energy. World leaders must find new sources of minerals, such as copper, essential to their transition to energy independence.

August 8, 2022 | stocknews.com

2 Pharmaceutical Stocks That Could Outperform the Market in the Long Term

August 8, 2022 | americanbankingnews.com

Merck & Co., Inc. (NYSE:MRK) Receives $97.41 Average PT from Analysts

August 7, 2022 | finance.yahoo.com

Merck defends tax approach against senator’s claims of avoidance

August 5, 2022 | finance.yahoo.com

How We're Supporting the Advancement of Women of Color at Our Company

August 5, 2022 | finance.yahoo.com

Myriad Genetics (MYGN) Q2 Earnings Top, Gross Margin Down

August 3, 2022 | finance.yahoo.com

Here’s Why You Should Consider Investing in Merck & Co. (MRK)

August 3, 2022 | finance.yahoo.com

Medicare Drug Pricing Changes Could Be Coming: Time to Ditch Pharma Stocks?

August 3, 2022 | finance.yahoo.com

Merck Provides Update on Phase 3 KEYNOTE-921 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer

August 3, 2022 | finance.yahoo.com

Merck and Eisai Provide Update on Phase 3 LEAP-002 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Versus LENVIMA Monotherapy in Patients With Unresectable Hepatocellular Carcinoma

August 2, 2022 | finance.yahoo.com

Henry Schein (HSIC) Q2 Earnings Top Estimates, '22 EPS View Up

August 2, 2022 | finance.yahoo.com

We Ran A Stock Scan For Earnings Growth And Merck (NYSE:MRK) Passed With Ease

August 1, 2022 | finance.yahoo.com

Looking for a Growth Stock? 3 Reasons Why Merck (MRK) is a Solid Choice

August 1, 2022 | finance.yahoo.com

Merck (MRK) Upgraded to Buy: Here's What You Should Know

August 1, 2022 | americanbankingnews.com

Merck & Co., Inc. (NYSE:MRK) Price Target Increased to $101.00 by Analysts at Barclays

July 31, 2022 | finance.yahoo.com

U.S. Would Gain Power to Negotiate Drug Prices Under Manchin-Schumer Bill

July 29, 2022 | finance.yahoo.com

Seagen's (SGEN) Earnings & Revenues Surpass Estimates in Q2

July 29, 2022 | finance.yahoo.com

Apple and Amazon’s Tech Strength Gets Bulls Buying Despite Recession on the Radar

July 28, 2022 | finance.yahoo.com

Merck (MRK) Q2 Earnings & Revenues Top, COVID Drug Helps Sales

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive MRK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merck & Co., Inc. and its competitors with MarketBeat's FREE daily newsletter.

MRK Company Calendar

Ex-Dividend for 7/8 Dividend: 6/14/2022
Dividend Payable: 7/08/2022
Last Earnings: 7/28/2022
Today: 8/12/2022
Ex-Dividend for 10/7 Dividend: 9/14/2022
Dividend Payable: 10/07/2022
Next Earnings (Estimated): 10/27/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Sector: Medical
Current Symbol: NYSE:MRK
CUSIP: 58933Y10
CIK: 310158
Web: www.merck.com
Phone: (908) 740-4000
Fax: 908-735-1253
Employees: 68,000
Year Founded: 1891

Price Target and Rating

Average Stock Price Forecast: $97.44
High Stock Price Forecast: $110.00
Low Stock Price Forecast: $85.00
Forecasted Upside/Downside: +9.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.61
Research Coverage: 18 Analysts

Profitability

EPS (Most Recent Fiscal Year): $6.53
Trailing P/E Ratio: 13.62
Forward P/E Ratio: 12.17
P/E Growth: 1.2
Net Income: $13.05 billion
Net Margins: 29.00%
Pretax Margin: 32.40%
Return on Equity: 48.45%
Return on Assets: 18.58%

Debt

Debt-to-Equity Ratio: 0.66
Current Ratio: 1.39
Quick Ratio: 1.14

Sales & Book Value

Annual Sales: $48.70 billion
Price / Sales: 4.63
Cash Flow: $7.30 per share
Price / Cash Flow: 12.19
Book Value: $17.10 per share
Price / Book: 5.20

Miscellaneous

Outstanding Shares: 2,533,280,000
Free Float: 2,525,933,000
Market Cap: $225.28 billion
Optionable: Optionable
Beta: 0.32

Social Links

Key Executives

Mr. Kenneth C. Frazier (Age 67)
Exec. Chairman
Comp: $4.58M
Mr. Robert M. Davis J.D. (Age 55)
Pres, CEO & Director
Comp: $4.4M
Ms. Caroline Litchfield (Age 53)
Exec. VP & CFO
Comp: $2.05M
Mr. Richard R. DeLuca Jr. (Age 59)
Exec. VP & Pres of Merck Animal Health
Comp: $2.05M
Dr. Dean Y. Li M.D. (Age 60)
Ph.D., Exec. VP & Pres of Merck Research Laboratories
Comp: $2.4M
Mr. David Michael Williams (Age 53)
Exec. VP and Chief Information & Digital Officer
Mr. Peter Dannenbaum
VP of Investor Relations
Ms. Jennifer L. Zachary (Age 44)
Exec. VP & Gen. Counsel
Lisa LeCointe-Cephas (Age 40)
Sr. VP and Chief Ethics & Compliance Officer
Ms. Jennifer Mauer
VP of Global Communications

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MRK Stock - Frequently Asked Questions

Should I buy or sell Merck & Co., Inc. stock right now?: 18 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 8 hold ratings, 9 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" MRK shares.
View MRK analyst ratings or view top-rated stocks.
What is Merck & Co., Inc.'s stock price forecast for 2022?: 18 analysts have issued 1 year price objectives for Merck & Co., Inc.'s shares. Their MRK share price forecasts range from $85.00 to $110.00. On average, they predict the company's stock price to reach $97.44 in the next year. This suggests a possible upside of 9.6% from the stock's current price.
View analysts price targets for MRK or view top-rated stocks among Wall Street analysts.
How have MRK shares performed in 2022?: Merck & Co., Inc.'s stock was trading at $76.64 at the start of the year. Since then, MRK stock has increased by 16.0% and is now trading at $88.93.
View the best growth stocks for 2022 here.
When is Merck & Co., Inc.'s next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our MRK earnings forecast.
How were Merck & Co., Inc.'s earnings last quarter?: Merck & Co., Inc. (NYSE:MRK) issued its earnings results on Thursday, July, 28th. The company reported $1.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.69 by $0.18. The company earned $14.59 billion during the quarter, compared to analysts' expectations of $13.85 billion. Merck & Co., Inc. had a trailing twelve-month return on equity of 48.45% and a net margin of 29.00%. Merck & Co., Inc.'s revenue was up 28.0% on a year-over-year basis. During the same quarter last year, the business posted $1.31 EPS.
How often does Merck & Co., Inc. pay dividends? What is the dividend yield for Merck & Co., Inc.?: Merck & Co., Inc. announced a quarterly dividend on Tuesday, July 26th. Stockholders of record on Thursday, September 15th will be paid a dividend of $0.69 per share on Friday, October 7th. This represents a $2.76 dividend on an annualized basis and a dividend yield of 3.10%. The ex-dividend date of this dividend is Wednesday, September 14th.
Read our dividend analysis for MRK.
Is Merck & Co., Inc. a good dividend stock?: Merck & Co., Inc. (NYSE:MRK) pays an annual dividend of $2.76 per share and currently has a dividend yield of 3.09%. The company has been increasing its dividend for 12 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 42.27%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, MRK will have a dividend payout ratio of 38.39% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for MRK.
What guidance has Merck & Co., Inc. issued on next quarter's earnings?: Merck & Co., Inc. issued an update on its FY 2022 earnings guidance on Thursday, August, 4th. The company provided earnings per share guidance of $7.25-$7.35 for the period, compared to the consensus estimate of $7.36. The company issued revenue guidance of $57.50 billion-$58.50 billion, compared to the consensus revenue estimate of $58.10 billion.

What is Kenneth C. Frazier's approval rating as Merck & Co., Inc.'s CEO?: 1,343 employees have rated Merck & Co., Inc. Chief Executive Officer Kenneth C. Frazier on Glassdoor.com. Kenneth C. Frazier has an approval rating of 94% among the company's employees. This puts Kenneth C. Frazier in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Merck & Co., Inc. own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include Pfizer (PFE), Johnson & Johnson (JNJ), AT&T (T), Intel (INTC), Cisco Systems (CSCO), Walt Disney (DIS), Verizon Communications (VZ), JPMorgan Chase & Co. (JPM), AbbVie (ABBV) and Home Depot (HD).
What is Merck & Co., Inc.'s stock symbol?: Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."
Who are Merck & Co., Inc.'s major shareholders?: Merck & Co., Inc.'s stock is owned by many different retail and institutional investors. Top institutional investors include Deutsche Bank AG (0.86%), California Public Employees Retirement System (0.56%), Swiss National Bank (0.43%), Clearbridge Investments LLC (0.33%), Sumitomo Mitsui Trust Holdings Inc. (0.33%) and Principal Financial Group Inc. (0.27%). Insiders that own company stock include Caroline Litchfield, Frank Clyburn, Julie L Gerberding, Kenneth C Frazier, Richard R Deluca, Rita A Karachun, Robert M Davis, Sanat Chattopadhyay and Wendell P Weeks.
View institutional ownership trends.
How do I buy shares of Merck & Co., Inc.?: Shares of MRK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Merck & Co., Inc.'s stock price today?: One share of MRK stock can currently be purchased for approximately $88.93.
How much money does Merck & Co., Inc. make?: Merck & Co., Inc. (NYSE:MRK) has a market capitalization of $225.28 billion and generates $48.70 billion in revenue each year. The company earns $13.05 billion in net income (profit) each year or $6.53 on an earnings per share basis.
How many employees does Merck & Co., Inc. have?: The company employs 68,000 workers across the globe.
When was Merck & Co., Inc. founded?: Merck & Co., Inc. was founded in 1891.
How can I contact Merck & Co., Inc.?: Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The official website for the company is www.merck.com. The company can be reached via phone at (908) 740-4000, via email at investor_relations@merck.com, or via fax at 908-735-1253.

This page (NYSE:MRK) was last updated on 8/12/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Merck & Co., Inc. - MRK Stock Forecast, Price & News

Merck & Co., Inc. MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Merck & Co., Inc. (NYSE:MRK) Stock

Wall Street Analysts Forecast Growth

Merck & Co., Inc. Trading Down 0.3 %

Merck & Co., Inc. Dividend Announcement

MRK Stock News Headlines

MRK Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

MRK Stock - Frequently Asked Questions

Should I buy or sell Merck & Co., Inc. stock right now?

What is Merck & Co., Inc.'s stock price forecast for 2022?

How have MRK shares performed in 2022?

When is Merck & Co., Inc.'s next earnings date?

How were Merck & Co., Inc.'s earnings last quarter?

How often does Merck & Co., Inc. pay dividends? What is the dividend yield for Merck & Co., Inc.?

Is Merck & Co., Inc. a good dividend stock?

What guidance has Merck & Co., Inc. issued on next quarter's earnings?

What is Kenneth C. Frazier's approval rating as Merck & Co., Inc.'s CEO?

What other stocks do shareholders of Merck & Co., Inc. own?

What is Merck & Co., Inc.'s stock symbol?

Who are Merck & Co., Inc.'s major shareholders?

How do I buy shares of Merck & Co., Inc.?

What is Merck & Co., Inc.'s stock price today?

How much money does Merck & Co., Inc. make?

How many employees does Merck & Co., Inc. have?

When was Merck & Co., Inc. founded?

How can I contact Merck & Co., Inc.?

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™